Kancera is a Swedish based biotechnology company that is developing a new class of small molecule drugs based on the fractalkine system. Fractalkine is a master regulator that controls immune cells and cancer cells with precision and therefore can play a crucial role to treat acute excessive inflammation and treatment resistant cancers. Kancera's lead drug candidate KAND567 is currently studied in a phase II trial to address the cardiac-protective effect of KAND567 following myocardial infarction. Kancera has also announced its intention to start a phase I/II study of KAND567 in ovarian cancer in the beginning of 2023. The stock is traded on the Nasdaq First North Premier Growth Market.
